DMRA net incomeQ3 2026-$31.99M
DMRA net income was -$31.99M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$3.13M a year earlier. For the full fiscal 2025 it was -$209.84M, compared with -$21.44M in fiscal 2024.
Damora Therapeutics Inc. (DMRA) financials
For the twelve months ended Sep 30, 2026, Damora Therapeutics Inc. reported -$291.68M of net income.
- Net income, TTM
- -$291.68M
- EPS, diluted, TTM
- $9.45
- Cash
- $349.66M
- Market cap
- $1.47B
FY2019FY2025
FY2021FY2022
DMRA revenue and earnings growth
DMRA EPSQ3 2026-$0.40
DMRA diluted EPS was -$0.40 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was $3.98, compared with -$18.53 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Research and development | $26.88M | $6.40M | $23.77M | $48.21M | $38.49M | $24.63M | $19.74M |
| Selling, general and admin | $9.69M | $10.50M | $12.69M | $13.00M | $13.74M | $9.01M | $2.44M |
| Operating income | -$210.87M | -$22.26M | -$39.91M | -$61.21M | -$52.23M | -$33.64M | $38.97M |
| Pre-tax income | -$209.79M | -$21.40M | -$38.35M | -$61.62M | -$51.75M | -$34.84M | -$36.51M |
| Income tax | $50.0K | $41.0K | $0 | $0 | $0 | $0 | $0 |
| Net income | -$209.84M | -$21.44M | -$38.35M | -$61.62M | -$51.75M | -$34.84M | -$36.51M |
| EPS, basic | $3.98 | -$18.53 | -$36.08 | -$60.75 | -$51.25 | -$190.50 | -$4045.50 |
| EPS, diluted | $3.98 | -$18.53 | -$36.08 | -$60.75 | -$51.25 | -$190.50 | -$4045.50 |
| Diluted shares | 1.4M | 1.2M | 1.1M | 1.0M | 1.0M | 182,908.08 | 10,398.64 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $257.62M | $14.18M | $21.46M | $32.79M | $62.56M | $163.84M | $11.53M |
| Short-term investments | $0 | - | $11.69M | $27.44M | $37.63M | - | - |
| Current assets | $260.42M | $16.84M | $36.77M | $63.91M | $110.10M | $169.29M | $56.08M |
| Total assets | $260.53M | $17.13M | $38.23M | $73.19M | $122.22M | $171.60M | $56.61M |
| Current liabilities | $20.07M | $1.20M | $5.83M | $11.11M | $4.54M | $5.57M | $7.93M |
| Total liabilities | $20.15M | $1.30M | $5.90M | $11.44M | $4.99M | $6.11M | $8.14M |
| Shareholders' equity | $239.04M | $14.47M | $32.33M | $61.75M | $117.22M | $165.49M | -$71.15M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.73M | -$18.62M | -$36.91M | -$42.93M | -$52.31M | -$38.20M | -$19.33M |
| Capital expenditures | - | - | - | $196.0K | $223.0K | - | - |
| Free cash flow | - | - | - | -$43.13M | -$52.53M | - | - |
| Investing cash flow | -$17.37M | $11.65M | $22.33M | $12.38M | -$48.05M | - | -$326.0K |
| Financing cash flow | $266.84M | - | $2.88M | $507.0K | - | $187.39M | - |
| Stock-based compensation | $998.0K | $3.24M | $5.43M | $5.57M | $4.48M | $982.0K | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Return on equity | -87.8% | -148.2% | -118.6% | -99.8% | -44.1% | -21.1% | - |
| Return on assets | -80.5% | -125.1% | -100.3% | -84.2% | -42.3% | -20.3% | -64.5% |
| Current ratio | 12.98 | 14.07 | 6.31 | 5.75 | 24.23 | 30.42 | 7.07 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $25.48M | $25.54M | $23.78M | $23.32M | $1.42M | $1.47M | $678.0K | $1.01M | $1.09M | $1.83M | $2.46M | $2.77M |
| Selling, general and admin | $11.39M | $9.45M | $7.03M | $4.07M | $1.74M | $1.96M | $1.92M | $1.70M | $2.75M | $2.77M | $3.28M | $3.18M |
| Operating income | -$36.86M | -$34.99M | -$30.81M | -$201.70M | -$3.16M | -$3.42M | -$2.60M | -$7.10M | -$3.84M | -$5.58M | -$5.74M | -$6.67M |
| Pre-tax income | -$31.99M | -$30.92M | -$27.74M | -$200.69M | -$3.13M | -$3.43M | -$2.53M | -$6.75M | -$3.88M | -$5.30M | -$5.48M | -$6.47M |
| Income tax | $0 | $255.0K | $42.0K | $44.0K | $0 | $4.0K | $2.0K | -$8.0K | $7.0K | $42.0K | $0 | - |
| Net income | -$31.99M | -$31.17M | -$27.78M | -$200.74M | -$3.13M | -$3.44M | -$2.53M | -$6.74M | -$3.88M | -$5.34M | -$5.48M | -$6.47M |
| EPS, basic | -$0.40 | -$0.39 | -$0.62 | $10.86 | -$2.36 | -$2.60 | -$1.92 | -$5.17 | -$3.39 | -$4.92 | -$5.05 | -$5.58 |
| EPS, diluted | -$0.40 | -$0.39 | -$0.62 | $10.86 | -$2.36 | -$2.60 | -$1.92 | -$5.17 | -$3.39 | -$4.92 | -$5.05 | -$5.58 |
| Diluted shares | 61.8M | 61.1M | 34.3M | - | 1.3M | 1.3M | 1.3M | - | 1.1M | 1.1M | 1.1M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $349.66M | $540.51M | $532.90M | $257.62M | $7.61M | $10.21M | $11.94M | $14.18M | $19.68M | $22.86M | $21.09M | $21.46M |
| Short-term investments | $178.82M | - | - | $0 | - | - | - | - | - | - | $6.08M | $11.69M |
| Current assets | $531.32M | $543.59M | $535.41M | $260.42M | $9.79M | $13.03M | $14.92M | $16.84M | $21.18M | $25.17M | $30.54M | $36.77M |
| Total assets | $532.63M | $543.64M | $535.44M | $260.53M | $10.74M | $13.69M | $15.37M | $17.13M | $23.38M | $27.30M | $32.48M | $38.23M |
| Current liabilities | $35.89M | $27.55M | $23.81M | $20.07M | $2.62M | $2.63M | $1.55M | $1.20M | $2.44M | $3.71M | $4.32M | $5.83M |
| Total liabilities | $36.87M | $27.58M | $23.84M | $20.15M | $2.73M | $2.74M | $1.66M | $1.30M | $2.44M | $3.71M | $4.32M | $5.90M |
| Shareholders' equity | $495.76M | $516.06M | $511.60M | $239.04M | $6.67M | $9.61M | $13.71M | $14.47M | $20.93M | $23.59M | $28.16M | $32.33M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.23M | -$21.87M | -$20.60M | $566.0K | -$2.62M | -$2.24M | -$2.44M | -$4.94M | -$3.65M | -$4.10M | -$5.94M | -$11.47M |
| Investing cash flow | - | - | - | - | - | - | - | $0 | $0 | $6.00M | $5.65M | $9.58M |
| Financing cash flow | $5.12M | $29.50M | $295.92M | - | - | - | - | - | - | - | - | $0 |
| Stock-based compensation | $7.54M | $6.14M | $3.13M | $483.0K | $164.0K | $172.0K | $179.0K | $308.0K | $681.0K | $891.0K | $1.36M | $1.09M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 14.80 | 19.73 | 22.48 | 12.98 | 3.73 | 4.96 | 9.62 | 14.07 | 8.68 | 6.79 | 7.07 | 6.31 |
Source: XBRL data Damora Therapeutics Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-25, first reported Nov 1, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
DMRA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| DMRA | - | - | -$291.68M | - | $1.47B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
DMRA FAQ
5 questionsIs DMRA profitable?
No. Damora Therapeutics Inc. reported a net loss of $291.68M for the twelve months ended Sep 30, 2026.How much cash and debt does DMRA have?
Damora Therapeutics Inc. reported $349.66M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is DMRA earnings per share?
Diluted earnings per share were $9.45 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did DMRA last report financial results?
The latest statements here come from Damora Therapeutics Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.Where does this DMRA financial data come from?
Quantisnow builds these statements from the structured XBRL data Damora Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.